Hydroxychloroquine in Children's Interstitial Lung Diseases With Genetic Causes

NCT04532346

Status	RECRUITING
Phase	Early Phase 1
Sponsor	Children's Hospital of Fudan University
Enrollment	60 participants

Key Eligibility Criteria

Inclusion (5)

- A clinical diagnosis of chILD with age\<18 years
- Genetically diagnosed (e.g. SFTPC, SFTPB, ABCA3, NKX2-1, CSF2RA, CSF2RB, IARS, MARS, COPA, SLC7A7, LRBA)
- Patients have to be clinically stable with no major changes in their medication in the last 4 weeks
- No HCQ treatment in the last 12 weeks
- Signed and dated informed consent of the subject (if subject has the ability) and the representatives (of underaged children) must be available before start of any specific trial procedures

Exclusion (5)

- Acute severe infectious exacerbations
- Known hypersensitivity to HCQ, or other ingredients of the tablets
- Proven retinopathy or maculopathy
- Renal insufficiency at screening, defined as glomerular filtration rate (GFR)\< 40 mL/min/1.73 m2 in patients aged 3 to 8 weeks\< 60 mL/min/1.73 m2 in patients e 8 weeks of age
- Participation in other clinical trials during the present clinical trial

Locations (1 total)

Children's hospital of Fudan University, Shanghai, Shanghai Municipality, China